World’s first Low Carbon Ratings system for Cement and Concrete launches
24.4.2025 10:00:00 CEST | Business Wire | Press Release
The Global Cement and Concrete Association (GCCA) announces the launch of Low Carbon Ratings (LCR) for Cement and Concrete - a first-of-its-kind transparent global rating system that will enable cement and concrete to be identified based on their carbon footprints. The ratings system is designed to help customers prioritise sustainability when selecting construction materials by using a clear and intuitive AA to G scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424485662/en/
GCCA Low Carbon Ratings for Cement and Concrete
Inspired by well-known appraising schemes such as the EU’s Energy Performance Certificates and the US Home Energy Rating System, the LCR offers a simple, transparent, and adaptable tool that helps builders, architects, governments, planners, and consumers everywhere in the world to make more informed and sustainable choices.
Thomas Guillot, Chief Executive of the GCCA, said: “Cement and concrete are the foundations of modern life - from the buildings we live and work in, to the roads we travel, and the infrastructure that supports clean water and green energy. As global demand for sustainable construction grows, the need for greater transparency around the carbon footprint of construction materials is more critical than ever.
“Our Low Carbon Ratings system supports more sustainable procurement practices and will empower the entire value chain to accelerate decarbonisation.”
The ratings system is designed to be easily recognisable – with a simple visual graphic that clearly indicates a product’s rating. The carbon rating system for cement and concrete provides consistency and comparability. Countries can adopt the global ratings as they are, or adapt them if local carbon accounting differs from global norms.
Riccardo Savigliano, Chief, Energy Systems and Decarbonization Unit, UNIDO said: “This is a huge step forward towards harmonizing global definitions for low emission cement and concrete in the support of decarbonization.”
With notable construction projects already demonstrating the use of lower carbon cement and concrete, the industry is making important progress. The launch of this global rating system marks another milestone on the road to greater sustainability.
Marlène Dance – Decarbonisation & Sustainable Design Expert, Bouygues Bâtiment International said: “We believe a globally consistent carbon rating system—adopted by all countries and used by all concrete suppliers—would be a game changer.
“We see great value in a simple, user-friendly tool, tailored for construction teams. It will help empower our site crews to better understand and manage the carbon footprint of the concrete they use.”
Mr Guillot added: “With this rating system in place, governments, policymakers and the private sector can now prioritise lower carbon cement and concrete in the procurement process which will in turn further stimulate the industry’s focus on decarbonising these essential building materials.”
Note to editors
The rating system is designed to be used with Environmental Product Declarations (EPDs) - which by definition are third party verified.
The rating system uses numerical definitions in units of embodied carbon dioxide equivalent per tonne for cement and per cubic metre of concrete product (ECO2e /m3), also referred to as Global Warming Potential (GWP), as calculated according to Environmental Product Declarations (EPDs) standards. These product definitions for “low carbon” and “near zero” carbon emissions were inspired from cement production definitions by the International Energy Agency and the GCCA 2050 Cement and Concrete Industry Roadmap for Net Zero Concrete.
The GCCA cement rating system can be adopted and applied in countries. Germany already provides a working example. The German Federal Ministry for Economic Affairs and Climate Action and VDZ (German Cement Association) developed a scheme that is fully aligned with the GCCA system and this is already implemented.
The GCCA worked with the Clean Energy Ministerial Industrial Deep Decarbonisation Initiative (IDDI) and stakeholders to create a set of globally applicable definitions for concrete. These are ready to use in the vast majority of countries. If a country has a different practice for product carbon accounting, then adaptation of the ratings can be done. This has already been completed in the UK.
The GCCA cement and concrete ratings can be used with national and local baselines and targets to support low carbon procurement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424485662/en/
Contacts
Paul Adeleke
Paul.Adeleke@gccassocation.org
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom